Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells by Liqun Chen & Lilly Y W Bourguignon
Chen and Bourguignon Molecular Cancer 2014, 13:52
http://www.molecular-cancer.com/content/13/1/52RESEARCH Open AccessHyaluronan-CD44 interaction promotes c-Jun
signaling and miRNA21 expression leading to
Bcl-2 expression and chemoresistance in breast
cancer cells
Liqun Chen and Lilly Y W Bourguignon*Abstract
MicroRNA-21 (miR-21) is associated with the development of solid tumors progression including breast cancer. In
this study we investigated matrix hyaluronan (HA)-CD44 (a primary HA receptor) interaction with c-Jun N-Terminal
Kinase (JNK)/c-Jun signaling in MDA-MB-468 breast cancer cells [a triple-negative (estrogen receptor-negative/
progesterone receptor-negative/HER2-negative) breast cancer cell line]. Our results indicated that HA binding to
CD44 promotes c-Jun nuclear translocation and transcriptional activation. Further analyses revealed that miR-21 is
regulated by an upstream promoter containing AP1 binding site(s), and chromatin immunoprecipitation (CHIP)
assays demonstrated that stimulation of miR-21 expression by HA/CD44 interaction is c-Jun-dependent in these
breast cancer cells. This process results in an increase of the anti-apoptosis protein Bcl-2 and upregulation of
inhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in MDA-MB-468 cells. Treatment with
c-Jun specific small interfering RNAs effectively blocks HA-mediated c-Jun signaling and abrogates miR-21
production as well as causes downregulation of survival proteins (Bcl-2 and IAPs) and enhancement of
chemosensitivity. In addition, our results demonstrated that anti-miR-21 inhibitor not only downregulates Bcl-2/IAP
expression but also increases chemosensitivity in HA-treated breast cancer cells. Together, these findings suggest
that the HA/CD44-induced c-Jun signaling plays a pivotal role in miR-21 production leading to survival protein
(Bcl-2/IAP) upregulation and chemoresistance in triple negative breast cancer cells such as MDA-MB-468 cell line.
This novel HA/CD44-mediated c-Jun signaling pathway and miR-21 production provide a new drug target for the
future intervention strategies to treat breast cancer.Introduction
Matrix Hyaluronan (HA) is an anionic, nonsulfated gly-
cosaminoglycan distributed widely throughout connective,
epithelial, and neural tissues [1]. As a major component in
the extracellular matrix of most mammalian tissues, HA
contributes significantly to cell adhesion, proliferation
and migration/invasion [2-4]. There is also a great deal of
evidence linking high level of HA production in human
carcinomas to aggressive phenotypes and metastasis, in-
cluding the progression of breast cancer [2-7].* Correspondence: lilly.bourguignon@ucsf.edu
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article, unless otherwise stated.CD44 is a family of cell-surface glycoproteins that are
expressed in a variety of tissues, including breast cancer
tissues [2,3]. RHAMM whose cell surface form is now
designated as CD168, was also found in breast cancer
cells [8,9]. Both CD44 and RHAMM mediate hyaluronan
signaling [10]. However, these two HA receptors likely
regulate cellular signaling by different mechanisms be-
cause they are not homologous proteins, are compart-
mentalized differently in the cell, and differ in the way
by which they bind to HA [10]. Since CD44 was identi-
fied as the first integral HA binding “receptor”, HA-
mediated CD44 signaling has received a great deal of
attention in cancer field. Both CD44 and HA are over-
expressed/elevated at sites of tumor attachment [1,4].
HA binding to CD44 not only affects cell adhesion toed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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lates a variety of tumor cell-specific functions leading to
breast cancer progression [2,3,11-14]. However, the
oncogenic mechanism(s) occurring during HA-activated
and CD44-specific breast cancer progression remain(s)
to be determined.
Jun N-terminal kinases (JNKs) belong to the mitogen-
activated protein kinase family, and are responsive to
stress stimuli, such as cytokines, ultraviolet irradiation,
heat shock, and osmotic shock [15]. Activation of JNKs
by targeting phosphorylation of downstream effector
proteins (e.g., c-Jun, ATF2, ELK1, SMAD4, p53 and
HSF1) leads to a number of important cellular functions
including cell growth, differentiation, survival and apop-
tosis [15,16]. Among these JNK-regulated target pro-
teins, c-Jun was initially identified as the c-Fos-binding
protein. The association between c-Jun and c-Fos forms
the AP-1 early response transcription factor complex
which then binds to DNA sequences located in the pro-
moter regions of genes stimulated by externally added
agonists [17]. In human cancer, the level of c-Jun and c-
fos mRNA and AP-1 expression has been shown to be
elevated in drug-resistant tumor cells (such as etoposide
resistant human leukemia K562 cells) as compared to the
c-Jun/c-fos mRNA/AP-1 levels found in drug-sensitive
parental lines [18]. Mitogenic stimulation of breast tumor
cells (MCF-7 cell line) by insulin or insulin-like growth
factors (IGFs) has been shown to promote c-Jun or c-fos
upregulation and AP-1 activity [19]. Previous studies
showed that persistent expression of c-Jun protein pre-
vents stromal cells from entering apoptosis during the late
secretory phase [20]. CD44 ligation blocks cell cycle pro-
gression of myeloid leukemia cells by downregulating c-
Jun expression [20]. These observations suggest that c-Jun
signaling is involved in regulating tumor cell growth, sur-
vival/anti-apoptosis and chemoresisitance.
MicroRNAs (miRNAs) are single-stranded RNAs of
21–25 nucleotides in length, which have been found to
modulate gene expression at the posttranslational level
[21]. MicroRNAs (miRNAs) are essential for normal
development as modulators of gene expression. An esti-
mated 30%-60% of the genome is regulated by miRNA-
mediated silencing [22], however aberrant expression of
miRNAs is associated with many diseases, including can-
cer. Recent studies indicate that that some microRNAs
upregulate the expression of its target gene by binding
to the 3′ UTR [23,24]. Overexpression of miR-21 influ-
ences cell proliferation, invasion, metastasis and che-
moresistance in different cancer cells including breast
cancer cells [25-27]. The identified targets of miR-21 in
human cancer cells include a tumor suppressor protein
[Program Cell Death 4 (PDCD4)] [28]. A previous study
indicated that HA-CD44 interaction promotes miR-21
production, and PDCD4 reduction in both breast cancercells (MCF-7 cell line) and head and neck cancer cells
(HSC-3 cell line) [25,29]. This event contributes to up-
regulation of inhibitors of apoptosis proteins (IAPs) and
the multidrug resistant protein (MDR1)/P-glycoprotein
(P-gp) resulting in anti-apoptosis and chemotherapy re-
sistance in breast tumor cells (MCF-7 cell line) [25].
Thus, miR-21 is currently considered to be an oncogene.
A recent report indicates that miR-21 can also stimulate
the expression of an anti-apoptosis protein, Bcl-2 by
binding directly to the 3′UTR of Bcl-2 mRNA [24]. Up-
regulation of Bcl-2 expression by miR-21 is associated
with anti-apoptosis, chemoresistance and proliferation in
pancreatic cancer cells [24]. The question of whether
Bcl-2 expression is associated with miR-21 production in
HA-treated breast tumor cells has not been addressed.
In this study we investigated a new HA/CD44-mediated
c-Jun signaling pathway that regulates miR-21 production
and chemoresistance in MDA-MB-468 cell line (a triple
negative breast cancer cell line). Our results indicated that
HA/CD44 activates c-Jun signaling which, in turn, stimu-
lates miR-21 expression and function. These events lead
to the production of an anti-apoptosis protein, Bcl-2 and
upregulation of survival proteins (IAPs) and Doxorubicin
chemoresistance in MDA-MB-468 cells. cells. Inhibition
of c-Jun signaling or silencing miR-21 expression/function
not only results in Bcl-2 downregulation, but also
causes a reduction of survival protein expression and
enhances chemosensitivity to Doxorubicin. Thus, our
findings strongly support the contention that HA/
CD44-regulated c-Jun and miR-21 form a functional
signaling axis that regulates tumor cell survival and
Doxorubicin chemoresistance in triple negative breast
cancer cells such as MDA-MB-468 cells.
Results
HA-CD44 interaction activates JNK and c-Jun signaling in
breast tumor cells
Previous studies [1,25,30-33] indicated that HA/CD44-
mediated oncogenic signaling plays an important role in
the development of several solid tumors including breast
cancer. Among the signaling aberrations present in
breast cancer, JNK and c-Jun signaling activation appears
to be one of the critical pathways for the development of
breast cancer [34,35]. Gene regulation by JNK-mediated
c-Jun signaling generally requires specific phosphoryl-
ation of these two molecules [36,37]. Specifically, JNK
phosphorylates c-Jun at Ser-63[pS63] residues within the
transcriptional activation domain of c-Jun [36]. In this
study we focused on the question of whether HA can
regulate JNK activation and c-Jun signaling in breast
tumor cells. To this end we examined a HA-mediated
phosphorylation of JNK and c-Jun. Using anti-phospho-
JNK[pS183]- and anti-phospho-c-Jun[pS63]-mediated
immunoblot or anti-c-Jun immunoblot, respectively, we
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occurs as early as 15 min following HA addition to
MDA-MB-468 cells (Figure 1-lane 2). In contrast, only a
relatively low level of phosphorylated JNK and c-Jun is
present in cells pretreated with anti-CD44 antibody plus
HA (Figure 1-lane 3) or without any HA treatment
(Figure 1-lane 1). However, non-immune rat IgG does
not appear to block HA-mediated JNK and c-Jun phos-
phorylation (lane 5 and 6). These results indicate that
phosphorylation of JNK and c-Jun is HA-dependent and
CD44-specific. Treatment of the JNK inhibitor (420116)
(Figure 1-lane 4) also effectively reduces HA-mediated
JNK and c-Jun phosphorylation (lane 5 and 6). These
observations clearly indicate that activation of JNK and
c-Jun is closely associated with HA-CD44 interaction in
MDA-MB-468 cells.
HA-CD44 binding promotes nuclear translocation of c-Jun
in MDA-MB-468 cells
HA/CD44-mediated nuclear translocation of transcrip-
tion factors is reported in a number of previous studies
[25,29,31,38]. In this study using immunofluorescence
staining and confocal microscopy, we observed that both
phosphorylated c-Jun[pS63] and c-Jun translocate from
the cytosol to the nucleus after 30 min HA treatment
(Figure 2A and 2B; Table 1). In contrast, most of the
phosphorylated c-Jun[pS63] (Figure 2A) and total c-Jun
(Figure 2B) is found in the cytosol, and only a low level










Figure 1 Detection of HA/CD44-induced JNK and c-Jun phosphoylation
with anti-JNK[pS183] antibody (a) or anti-c-Jun[pS63] antibody (b) or anti-c-Jun
no HA (lane 1) or with HA (50 μg/ml) for 15min (lane 2) or pretreated with ant
or pretreated with JNK inhibitor (420116) (20 μM) for 1 h followed by 15min H
(lane 5) or treated with non-immune rat IgG plus HA (lane 6). [The ratio of pho
control) (c) was determined by densitometry, and the levels were normalized t
(without HA treatment) (designated as 1.00); the values expressed represent an
than 5%].nucleus of MDA-MB-468 cells- either pretreated with
anti-CD44 antibody plus HA (Figure 2A and 2B; Table 1)
or without any HA treatment (Figure 2A and 2B). How-
ever, non-immune Rat IgG fails to reduce HA-mediated
c-Jun and p-c-Jun nuclear accumulation (Table 1). These
results indicate that nuclear translocation of c-Jun or p-
c-Jun is HA-dependent and CD44-specific. We also
noted that neither phosphorylated-c-Jun[pS63] nor total
c-Jun undergoes nuclear translocation in cells treated
with JNK Inhibitor, 420116 plus HA (Figure 2A and
Figure 2B).
The reason for showing both phospho-c-Jun and total
c-Jun in MDA-MB-468 cells following HA treatment is
to determine whether phosphorylated c-Jun represents
the majority or a minority species of total c-Jun. The fact
that the JNK inhibitor prevents nuclear translocation of
both phospho-c-Jun and Jun suggests that majority of c-
Jun is phosphorylated by JNK. This explains the effect of
JNK inhibitor on blocking both phosphorylated c-Jun
and total c-Jun nuclear accumulation in cells treated
with HA. These findings strongly suggest that the HA-
CD44 interaction promotes c-Jun nuclear translocation
in MDA-MB-468 cells in a JNK-dependent manner.
Role of c-Jun in regulating miR-21 gene expression in
HA/CD44
A previous study indicated that miR-21 is regulated by
an upstream/enhancer promoter containing AP1 binding







in MDA-MB-468 cells. NP-40 solubilized cell lysates were immunoblotted
antibody (c) as a loading control using MDA-MB-468 cells treated with
i-CD44 antibody for 1 h followed by 15min HA (50 μg/ml) addition (lane 3)
A (50 μg/ml) addition (lane 4) or treated with non-immune IgG without HA
sphorylated c-JNK (a) or phosphorylated c-Jun (b) and c-Jun (the loading
o untreated (without HA treatment) value or non-immune rat IgG
average of triplicate determination of 4 experiments with an SD of less





























Figure 2 Immunocytochemical analyses of HA/CD44-induced nuclear translocation of phospho-c-Jun/c-Jun in MDA-MB-468 cells.
MDA-MB-468 cells [untreated or pretreated with anti-CD44 antibody or JNK inhibitor (420116) (20 μM) for 1 h] were incubated with HA (50 μg/ml)
(or without HA) for 30 minutes at 37°C and fixed by 2% paraformaldehyde. Subsequently, these cells were rendered permeable by ethanol
treatment and immunostained with Texas Red-labeled anti-p-c-Jun (red color) (A, D, G, J) and DAPI (a nuclear marker) (B, E, H, K) or FITC-labeled
anti-c-Jun (green color) (Insert-a, d, g, j) and DAPI (a nuclear marker) (Insert-b, e, h, k). [Overlay images represent simultaneous localization of Texas
Red-labeled p-c-Jun (red color) and DAPI (a nuclear marker) (C, F, I, L) or FITC-labeled anti-c-Jun (green color) and DAPI (a nuclear marker) (c, f, i, l)].
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moter, anti-c-Jun antibody or anti-phospho-c-Jun [pS63]-
specific chromatin immunoprecipitation (ChIP) assays
were performed on MDA-MB-468 cells. As shown in
Figure 3, the PCR from anti-c-Jun or anti-phospho-c-Jun
[pS63]-mediated precipitations from HA-treated MDA-
MB-468 cells resulted in a specific amplification product
using a primer pair specific for the miR-21 promoter/Table 1 Measurement of HA-induced p-c-Jun and c-Jun nucle
Treatments p-c-Jun nuclear accumulation (%
No HA (control) 100% ± 5
+ HA 275% ± 13a
Non-immune IgG (No HA) 102% ± 4a
Non-immune IgG (+HA) 268% ± 9a
Anti-CD44 antibody + HA 92% ± 3a
Vehicle control + HA 262% ± 8a
JNK inhibitor + HA 84% ± 4a
p-c-Jun or c-Jun was detected in the nucleus which was stained with Texas Red-lab
ure 2). The labeling index for p-c-Jun or c-Jun was indeoendently determined by tw
accumulatiohjn among 1,000 cells using Epi-fluorescence microscope (at 40X objec
All data represent mean ± SEM (with n = 4) of p-c-Jun and c-Jun nuclear accumulat
a, bStatistically significant (P < 0.005; analysis of variance; n = 4) as compared with coenhancer region containing the AP1 binding sites
(Figure 3A-a, b-lane 2). In contrast, a reduced amount
of the c-Jun or phospho-c-Jun binding of miR-21 up-
stream/enhancer promoter region was detected in cells
pretreated with anti-CD44 antibody followed by HA
addition (Figure 3A-a, b-lane 3), or without HA treat-
ment (Figure 3A-a, b-lane 1). However, non-immune rat
IgG does not appear to block HA-mediated c-Jun andar accumulation in MDA-MB-468 cells








eled anti-p-c-Jun antibody or FITC-labeled anti-c-Jun antibody (as shown in Fig-
o observers and corresponded to the percentage of positive nuclear
tives).
ion activity detected in each sample.
ntrol samples (No HA treatment).
d: Input 





1 2 3 4 5 1 2
ChIP Assay 
1 2
c-Jun IP/Input = 
p-c-Jun IP/Input =
1.00  2.69  1.02     1.00   2.70
1.00  2.72  1.05      1.00   2.65
2.65   0.83 2.60   1.15
2.60   0.75 2.55   1.05
IgG IP/Input = ND   ND ND ND ND ND     ND ND ND
Figure 3 Analyses of an in vivo binding of c-Jun (or phosphorylated c-Jun) to the miR-21 upstream promoter/enhancer region in MDA-
MB-468 cells. In order to analyze the interaction between c-Jun/phospho-c-Jun and the upstream promoter/enhancer region of miR-21 promoter in
MDA-MB-468 cells, ChIP assay was performed in MDA-MB-468 cells following protocols described in Materials and methods using the AP1 binding site
containing miR-21 promoter (upstream promoter/enhancer region)-specific primers by PCR. Identical volumes from the final precipitated materials were
used for the PCR reactions [untreated cells (A: lane 1); cells treated with HA for 1 h (A: lane 2); cells pretreated with anti-CD44 antibody plus 1 h HA
addition (A: lane 3); cells treated with non-immune rat IgG (without HA addition) (A: lane 4) or cells treated with non-immune rat IgG plus 1 h HA
addition (A: lane 5); or cells treated with vehicle control plus 1h HA addition (B: lane 1) or treated with JNK inhibitor plus 1h HA addition (B: lane 2);
or cells pretreated with scrambled siRNA plus 1h HA addition (C: lane 1); or cells pretreated with c-Jun siRNA plus 1h HA addition (C: lane 2)]. (a: anti-c-
Jun-mediated immunoprecipitated material; b: anti-phospho-c-Jun[pS63]-mediated immunoprecipitated material; c: IgG isotype control-mediated
precipitated material; d: total input materials). [The ratio of c-Jun IP materials (a) or phosphorylated c-Jun IP materials (b) or IgG IP materials (c) and total
Input materials (the loading control) (d) was determined by densitometry, and the levels were normalized to untreated (without HA treatment)
value or non-immune IgG (without HA treatment) (designated as 1.00); the values expressed represent an average of triplicate determination of
4 experiments with an SD of less than 5%]. ND represents Not Detectable.
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a, b-lane 4 and 5). These findings suggest that the recruit-
ment of c-Jun (also phospho-c-Jun) into the upstream/
enhancer region of miR-21 promoter site is HA-specific
and CD44-dependent.
To confirm the direct involvement of JNK-mediated c-
Jun signaling in miR-21 gene upregulation, JNK activity
was blocked by a JNK Inhibitor, 420116, (Figure 3B) and
c-Jun was downregulated by c-Jun small interfering RNA
(siRNA), (Figure 3C) followed by the miR-21 promoter-
specific ChIP assay as described above. Our results indi-
cate that (i) inhibition of c-JNK (but not vehicle control
samples) (Figure 3B-a, b-lane 2 vs. lane 1) or (ii) transfec-
tion of MDA-MB-468 cells with c-Jun siRNAs (but not
scrambled sequenced siRNA) (Figure 3C-a, b-lane 2 vs.
lane 1) effectively blocked HA-mediated c-Jun/phospho-c-
Jun binding to the miR-21 upstream/enhancer promoter
region with AP1 binding sites in MDA-MB-468 cells.Identical amplification products were detected in the posi-
tive controls from total input chromatin (Figure 3A, B, C-
d-all lines). Moreover, no amplification was seen in sam-
ples that were processed by IgG isotype control-mediated
precipitation (Figure 3A, B, C-c-all lanes). Therefore, we
concluded that downregulation of JNK activity or c-Jun/
phospho-c-Jun expression by either JNK inhibitor
(420116) or c-Jun siRNA is specific.
HA-CD44-activated JNK/c-Jun signaling stimulates
miRNA-21 production in MDA-MB-468 Cells
The expression of mature miR-21 is involved in breast
cancer progression [31,40]. To determine whether miR-
21 levels are increased following the binding of HA to
CD44, we first prepared small RNAs followed by an
RNase protection assay using the miRNA Detection Kit
(Ambion). Our results indicated that the level of miR-21
is definitely increased in MDA-MB-468 cells treated
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not treated with HA (Figure 4a-lane 1) or with anti-
CD44 antibody treatment plus HA addition (Figure 4a-
lane 3). However, non-immune rat IgG does not inhibit
HA-mediated miR-21 production (lane 10 and 11).
These results indicate that miR-21 expression is HA-
dependent and CD44-specific in MDA-MB-468 cells.
Transfection of these cells with c-Jun siRNA (Figure 4a-
lane 5) caused significantly less HA-induced miR-21 ex-
pression compared to those cells treated with scrambled
siRNA (Figure 4a-lane 4). These findings support the
notion that c-Jun is required for miR-21 production in
HA-activated MDA-MB-468 cells. Moreover, we found
that the expression of miR-21 can be induced in cells
treated with a miRNA-negative control upon addition
of HA (Figure 4a-lane 6). In contrast, the treatment
of MDA-MB-231 cells with an anti-miR-21 inhibitor
plus HA resulted in a decrease in miR-21 expression
(Figure 4a-lane 7). Treatment of MDA-MB-468 cells
with a JNK inhibitor (420116) also significantly attenu-
ated HA-CD44-induced miR-21 production as compared
to vehicle-treated cells with HA addition (Figure 4a-lane
8 and lane 9). We believe that these changes in miR-21
expression under various treatment conditions are not
due to the variations of RNA extracted from each sam-
ple since there were very similar levels of miR-191 (as a
loading control) in all samples (Figure 4b-lane 1-9). To-
gether, these findings strongly indicate that HA/CD44-
activated JNK/c-Jun signaling plays an important role in




1 2 3 4 5
miR-21/miR-191= 1.00     2.89    0.84     2.76      0.78     
Figure 4 Detection of HA/CD44-induced miR-21 production in MDA-M
protection assay as described in Materials and methods. a: Autoradiogram
(a: lane 1) or with 2 h HA treatment (a: lane 2) or pretreated with anti-CD4
incubated with scrambled siRNA plus 2 h HA treatment (a: lane 4) or c-Jun
miRNA control plus 2 h HA treatment (a: lane 6) or incubated with anti-miR
(a: lane 8) or pretreated cells with JNK Inhibitor (420116) plus 2 h HA treatm
(lane 10) or treated with non-immune IgG (with HA addition for 2 h). [Auto
control]. [The ratio of miRNA-21 (a) and miRNA-191 (the loading control) (b
untreated (without HA treatment) value or non-immune IgG (without HA t
average of triplicate determination of 4 experiments with an SD of less thaThe impact of HA/CD44-mediated miR-21 (induced by
c-Jun signaling) on Bcl2/IAP expression, anti-apoptosis
and chemoresistance in MDA-MB-468 cells
Bcl-2 is identified as one of the target proteins induced
by miR-21 [24]. Inhibitors of the apoptosis family of pro-
teins (IAPs) [cIAP-1, cIAP-2 and X-linked IAPs (XIAP)]
are frequently overexpressed by cancer cells. Import-
antly, upregulation of IAPs is linked to chemoresistance
due to binding to caspases and suppressing apoptosis
[41]. Here, we demonstrated that the expression of both
Bcl2 and IAPs (cIAP1/cIAP2/XIAP) is greatly enhanced
in cells treated with HA (Figure 5A-a, b, c, d-lane 2). In
contrast, low basal levels of Bcl2 expression and IAPs
(cIAP1/cIAP2/XIAP) exist in untreated cells (Figure 5A-
a, b, c, d-lane 1) or cells pretreated with anti-CD44 anti-
body followed by HA addition (Figure 5A-a, b, c, d-lane 3).
The fact that non-immune rat IgG fails to block HA-
mediated Bcl2 and IAPs (cIAP1/cIAP2/XIAP) expression
(Figure 5A-a, b, c, d-lane 4 and 5) suggests that up-
regulation of Bcl2 and IAPs (cIAP1/cIAP2/XIAP) is HA-
dependent and CD44-specific. Further analyses indicated
that the expression of both Bcl2 and IAPs is significantly
downregulated in MDA-MB-468 cells treated with c-
Jun siRNA (Figure 5B-a, b, c, d-lane 3) or JNK inhibitor
(Figure 5C-a, b, c, d-lane 4). However, both Bcl2 and IAPs
are up-regulated in MDA-MB-468 cells treated with scram-
bled sequence siRNA in the presence of HA (Figure 5B-a, b,
c, d-lane 2) as compared to no HA addition (Figure 5B-a, b,
c, d-lane 2). These results suggest that HA/CD44-mediated
JNK/c-Jun signaling is closely linked to the expression ofase protection Assay 
6 7 8 9 10 11
2.85     0.52      2.82      0.78 1.00         2.69       
B-468 cells. Detection of miR-21 in MDA-MB-468 cells using RNase
of miR-21 detected in MDA-MB-468 cells incubated without HA
4 antibody for 1 h followed by HA addition for 2 h (a: lane 3) or
siRNA plus 2 h HA treatment (a: lane 5) or incubated with negative
NA-21 plus 2 h HA treatment (a: lane 7) or 2 hours HA treatment
ent (a: lane 9) or treated with non-immune IgG (without HA addition)
radiogram of miR-191 (b) in each gel lane was used as a loading
) was determined by densitometry, and the levels were normalized to
















1.00       2.24
1.00       2.30
1.00    2.22      1.42
1.00    2.65      1.03
1.00    2.63      0.77
1.00       2.33
1.00       2.30
1.00     2.70    1.35
1.00     2.80    1.40
1.00     2.89     1.50
1.00     2.75     1.04
1.00  2.25  0.80  0.65
1.00  2.42  1.15  0.60
1.00  2.80  1.10  1.24
1.00  2.77   1.05  1.02
Figure 5 Analyses of HA/CD44-mediated Bcl-2 and IAP expression in MDA-MB-468 cells. (A) Cell lysates from cells [treated with no HA
(lane 1) or with HA (lane 2) or pretreated with anti-CD44 antibody plus HA (lane 3) or treated with non-immune IgG (without HA) (lane 4) or with
HA (lane 5)] were immunoblotted with anti-BCL-2 antibody (a) or anti-cIAP-1 antibody (b) or anti-cIAP-2 antibody (c) or anti-XIAP antibody (d) or
anti-actin antibody (e), respectively. [The ratio of Bcl2 (a) or cIAP1 (b) or cIAP2 (c) or XIAP (d) and actin (c) was determined by densitometry, and
normalized to untreated (without HA treatment) value or non-immune IgG (no HA) (designated as 1.00)]. (B) Cell lysates from cells [transfected
with scrambled siRNA with no HA (lane 1) or with HA (lane 2) or transfected with c-Jun siRNA plus HA (lane 3)] were immunoblotted with
anti-BCL-2 antibody (a) or anti-cIAP-1 antibody (b) or anti-cIAP-2 antibody (c) or anti-XIAP antibody (d) or anti-actin antibody (e), respectively.
[The ratio of Bcl2 (a) or cIAP1 (b) or cIAP2 (c) or XIAP (d) and actin (e) was determined by densitometry, and normalized to the value of scrambled
siRNA-treated samples (no HA) (designated as 1.00)]. (C) Cell lysates from cells [transfected with negative miRNA control plus no HA (lane 1) or
with HA (lane 2) or transfected with anti-miRNA-21 plus HA (lane 3) or treated with JNK inhibitor plus HA (lane 4)] were immunoblotted with
anti-cIAP-1 antibody (a) or anti-cIAP-2 antibody (b) or anti-XIAP antibody (c) or anti-actin antibody (e), respectively. [The ratio of Bcl2 (a) or cIAP1
(b) or cIAP2 (c) or XIAP (d) and actin (e) was determined by densitometry, and normalized to the value of negative control miRNA-treated samples
(no HA) (designated as 1.00)]. The values expressed represent an average of triplicate determination of 4 experiments with an SD of less than 5%.
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noted that downregulation of miR-21 by treating MDA-
MB-468 cells with an anti-miR-21 inhibitor (but not a
negative-control miRNA) promotes downregulation of
Bcl2 and IAPs (cIAP1/cIAP2/XIAP) (Figure 5C-a, b, c, b-d,
lane 3 vs. lane 1 and lane 2) in the presence of HA. These
results indicate that the signaling network consisting of
JNK/c-Jun signaling and miR-21 is functionally coupled
with the up-regulation of anti-apoptosis and survival pro-
tein (e.g., Bcl2, cIAP1/cIAP2/XIAP) production. These
specific effects likely facilitate the oncogenic progres-
sion of HA/CD44-activated MDA-MB-468 cells.
Finally, further analyses showed that the addition of
HA enhances cell growth/survival and reduces apop-
tosis in untreated control cells or anti-CD44 antibody
treated cells (but not non-immune rat IgG treated cells)
(i.e., without chemotherapeutic drugs) and decreases
the ability of Doxorubicin to induce tumor apoptosis
and cell death (Table 2A). These observations indicated that
HA causes both a decrease in apoptosis and an increase in
breast tumor cell growth and survival (Table 2A & B) lead-
ing to the enhancement of chemoresistance (Table 2A).Moreover, downregulation of c-Jun or miR-21 [by treating
MDA-MB-468 cells with c-Jun siRNA, JNK inhibitor or
transfected MDA-MB-468 cells with an anti-miR-21 in-
hibitor (but not scrambled sequence siRNA or with
miRNA-negative control)] effectively attenuates HA-
mediated tumor cell growth/anti-apoptosis/survival and
enhances chemotherapy sensitivity in MDA-MB-231
cells (Table 2A & B). Taken together, these findings
strongly suggest that the HA/CD44-mediated JNK/c-
Jun signaling pathways and miR-21 function represent
new treatment targets to force tumor cells to undergo
apoptosis/death and to overcome chemotherapy resist-
ance in breast cancer cells.
Discussion
Hyaluronan (HA) is an important structural component
of the extracellular matrix (ECM). In cancer patients,
the level of HA is usually higher in malignant tumors
than in corresponding benign or normal tissues, and in
some tumor types the level of HA is predictive of malig-
nancy [2-7,42]. In particular, HA level is elevated in the
serum of breast cancer patients [4,42]. The aberrant HA
Table 2 Measurement of doxorubicin-induced MDA-MB-468 cell apoptosis and growth inhibition





No doxorubicin + doxorubicin
(A) Effects of various signaling perturbation agents on doxorubicin–induced apoptosis and cell growth inhibition in MDA-MB-468 cells.
(a) Effects of Doxorubicin-induced apoptosis and cell growth inhibition in MDA-MB-468 cells following HA treatment:
No HA (Untreated cells) 4.1 ± 0.5 30.2 ± 3.1a 73.5 ± 5.1
+ HA 2.4 ± 0.3a 12.6 ± 2.3a 188.0 ± 10.5b
Non-immune rat IgG-treated cells (No HA) 3.8 ± 0.5a 29.2 ± 2.2a 70.3 ± 4.1b
Non-immune rat IgG-treated cells (+ HA) 2.2 ± 0.2a 10.5 ± 2.0a 176.0 ± 10.3b
Anti-CD44-treated cells (+ HA) 3.8 ± 0.2a 29.2 ± 2.2a 28.4 ± 3.6b
(b) Effects of Doxorubicin-induced apoptosis and cell growth inhibition in MDA-MB-468 cells treated with c-Jun siRNA plus HA:
Scrambled siRNA-treated cells (No HA) 5.2 ± 0.6 32.4 ± 3.6c 85.0 ± 2.4
Scrambled siRNA-treated cells (+ HA) 4.5 ± 0.5c 11.9 ± 3.1c 190.0 ± 6.00d
c-Jun siRNA-treated cells (No HA) 5.2 ± 0.6c 33.6 ± 2.8c 40.5 ± 0.30d
c-Jun siRNA-treated cells (+ HA) 4.5 ± 0.5c 31.9 ± 3.2c 39.2 ± 0.80d
(c) Effects of Doxorubicin-induced apoptosis and cell growth inhibition in MDA-MB-468 cells treated with anti-miR-21 inhibitor plus HA:
miRNA negative control-treated cells (No HA) 3.7 ± 0.4 31.6 ± 2.9e 62.8 ± 0.5
miRNA negative control-treated cells (+ HA) 2.5 ± 0.2e 12.3 ± 0.4e 196.0 ± 4.2f
Anti-miR-21 inhibitor-treated cells (No HA) 3.2 ± 0.6e 38 ± 2.5e 65.0 ± 3.0f
Anti-miR-21 inhibitor-treated cells (+ HA) 3.1 ± 0.4e 34 ± 2.1e 70.0 ± 0.2f
(B) Effects of JNK inhibitor (420116) on Doxorubicin-induced apoptosis and cell growth inhibition in MDA-MB-468 cells.
Vehicle control-treated cells (No HA) 4.3 ± 0.2 32 ± 2.4g 64.00 ± 6.2
Vehicle control-treated cells (+ HA) 2.6 ± 0.4g 14 ± 0.5g 180.0 ± 10.0h
JNK inhibitor (420116)-treated cells (No HA) 12.0 ± 0.5g 35 ± 2.6g 26.0 ± 3.5h
JNK inhibitor (420116)-treated cells (+ HA) 3.2 ± 0.3g 38 ± 3.3g 25.0 ± 0.2h
*Cells were designated apoptotic when displaying Annexin V-positive staining. In each sample, at least 500 cells from five different fields were counted, with the
percentage of Doxorubicin or JNK inhibitor (420116) (2 h treatment)-induced apoptotic cells calculated as Annexin V-positive cells/total number of cells. The values
are presented as the means ± standard deviation. All assays consisted of at least six replicates and were performed on at least 4 different experiments.
**Tumor cell growth inhibition (IC50) is designated as “the μM concentration of chemotherapeutic drug (e.g., Doxorubicin-24 h treatment) that causes 50%
inhibition of tumor cell growth” using MTT-based growth assay as described in the Materials and methods. IC50 values are presented as the means ± standard
deviation. All assays consisted of at least six replicates and were performed on at least 4 different experiments.
a, bStatistically significant (P < 0.005; analysis of variance; n = 4) as compared with control samples (No HA treatment).
c, dStatistically significant (P < 0.005; analysis of variance; n = 4) as compared with control samples (scrambled siRNA-treated cells without HA addition).
e, fStatistically significant (P < 0.005; analysis of variance; n = 4) as compared with control samples (miRNA negative control-treated cells without HA addition).
g, hStatistically significant (P < 0.001; analysis of variance; n = 4) as compared with control samples (vehicle control-treated cells without HA addition).
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degradation into LMW-HA by hyaluronidases [46] are
thought to be closely associated with breast tumor cell
progression [4].
HA binds specifically to CD44, a family of multifunc-
tional transmembrane glycoproteins expressed in nu-
merous cells and tissues, including breast tumor cells
and various carcinoma tissues [2-4]. The crystal struc-
ture of the HA-CD44 complex was reported previously
and a single HA binding site was identified [47]. CD44 is
generally expressed in a variety of isoforms that are
products of a single gene generated by alternative spli-
cing of variant exons inserted into an extracellular
membrane-proximal site [48,49]. CD44 is also expressed
in tumor stem cells that have the unique ability toinitiate tumor cell-specific properties [38,50]. In fact,
CD44 is considered to be one of the important surface
markers on cancer stem cells [38,50]. HA binding to
CD44 is involved in the stimulation of both receptor ki-
nases (e.g., ErbB2, EGFR and TGFβ receptors) and non-
receptor kinases (e.g., c-Src and ROK) [3] required for a
variety of tumor cell-specific functions leading to tumor
progression.
Abnormal JNK/c-Jun signaling also appears to play a
critical role in oncogenesis [34,35]. JNK-activated c-Jun
is a signal-transducing transcription factor of the AP-1
family that is implicated in cell cycle progression, differ-
entiation and cell transformation [51]. It has a direct role
in regulating the transcription of p53 and cyclinD1
[52,53]. It has also been shown that c-Jun accelerates
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quired for cell cycle progression in tumor cells [51]. The
AP-1 factor c-Jun is thought to act as a “bodyguard”,
preventing methylation of a distinct set of genes after
oncogenic transformation [51]. Recently, c-Jun is found to
trigger miR-21 transcription through AP-1 binding sites
present in the miR-21 promotor region [39]. In this study
we observed that HA-CD44 binding results in c-Jun (also
causes phosphorylation of c-Jun) nuclear localization in
MDA-MB-468 cells (Figure 2). Thus, identifying specific
genes that are transcriptionally controlled by the JNK/c-
Jun signaling during HA-CD44 interaction in the nucleus
may be essential for understanding the disease mechanism
occurring during breast cancer progression.
Overexpression of miR-21 is detected in various breast
cancer cell lines and patient specimens [25,26]. Accumu-
lating evidence indicates that miR-21 is closely associ-
ated with both cancer development and chemotherapy
resistance [25]. The stem cell marker, Nanog, has been
found to be involved in the regulation of pri-miRNA ex-
pression during cancer development [25]. Our previous
work indicated that HA/CD44-activated PKCε promotes
Nanog interaction with p68 and DROSHA leading to
biosynthetic processing and production of miR-21 in
breast tumor cells [25]. These findings suggest that HA/
CD44-mediated Nanog signaling is closely linked to
miR-21 production and function during oncogenesis.
In this study, we provided new evidence that miR-21
expression is controlled by an upstream promoter/
enhancer containing AP-1 binding sites in MDA-MB-
468 cells while chromatin immunoprecipitation (ChIP)
assays demonstrate that stimulation of miR-21 produc-
tion by HA is JNK and c-Jun-dependent in breast tumor
cells (Figure 4). Most importantly, downregulation of
JNK/c-Jun signaling (by treating cells with JNK inhibitor
or c-Jun siRNA) or miR-21 (by treating cells with anti-
miR-21 inhibitor) reduces the expression of the target
protein, Bcl2, and anti-apoptotic proteins [e.g., IAPs
(cIAP1/cIAP2/XIAP)] (Figure 5) in breast tumor cells.
Determining the cellular and molecular mechanisms in-
volved in the regulation of these causal links between
JNK/c-Jun signaling and miR-21 function, including Bcl2
and IAP upregulation, awaits further investigation.
Chemotherapy resistance is one of the primary causes
of morbidity in patients diagnosed with solid tumors in-
cluding breast cancer [54-56]. Chemotherapeutic agents,
such as doxorubicin, are commonly used to inhibit DNA
synthesis in the treatment of breast cancer patients [57].
In particular, the ability of doxorubicin to bind to DNA
and/or produce free radicals is thought to be the mech-
anism for the induction of cytotoxic effects on tumor
cells [57]. However, this drug often displays limited cyto-
toxic killing and anti-tumor effects due to chemoresis-
tance which occurs in de novo tumor cells [57].It is now certain that a number of oncogenic signaling
pathways are closely involved with chemotherapeutic drug
resistant phenotypes [25,29-31,38,58,59]. In particular,
matrix HA interaction with CD44 in cancer cells have been
strongly implicated in the development of chemoresistance
[25,29-31,38,58,59]. Specifically, HA is capable of stimulat-
ing MDR1 (P-gp) expression and drug resistance in breast
tumor cells [30,58,59]. CD44 also interacts with MDR1
(P-gp) to promote cell migration and invasion of breast
tumor cells [30,58,59]. Previously we reported that acti-
vation of HA-CD44-mediated oncogenic signaling events
[e.g., mir-302/miR-21, intracellular Ca2+ mobilization, epi-
dermal growth factor receptor (EGFR)-mediated ERK sig-
naling, topoisomerase activation, and ankyrin-associated
cytoskeleton function] leads to multidrug resistance in
a variety of tumor cells [3,10,33]. These observations
strongly suggest a functional link between HA-mediated
CD44 signaling and drug resistance.
In this study we demonstrated that HA/CD44-acti-
vated JNK/c-Jun signaling and miR-21 increases survival
protein, Bcl2, resulting in oncogenesis by enhancing the
expression of inhibitors of anti-apoptosis proteins (IAPs)
(Figure 5). Furthermore, downregulation of HA/CD44-
activated JNK/c-Jun signaling (by JNK I nhibitor/c-Jun
siRNA) and miR-21 production (by anti-miR-21 inhibi-
tor) not only reduces Bcl2 upregulation (Figure 5), but
also inhibits the expression of survival proteins (e.g., c-
IAP1, c-IAP2 and XIAP) (Figure 5). Consequently, these
signaling perturbation events contribute to apoptosis
and chemosensitivity (Table 1). Furthermore, this newly-
discovered HA/CD44-activated JNK/c-Jun signaling path-
way and miR-21 production/function should provide
important new drug targets to cause tumor cell apop-
tosis and overcome chemotherapy resistance in breast
tumor cells.
In summary (as shown in Figure 6), we propose that
HA-CD44 binding (Step 1) promotes JNK and c-Jun (also
serine phosphorylated JNK/c-Jun) (step 2). Subsequently,
c-Jun (also p-c-Jun) translocates from the cytosol to the
nucleus and interacts with an upstream/enhancer region
(containing AP1 binding sites) of the miR-21 promoter
(step 3), resulting in miR-21 gene expression (step 4) and
mature miR-21 production (step 5). The resultant miR-21
then functions to upregulate the survival protein, Bcl2
(step 6a) and promotes MDA-MB-468 cell activation lead-
ing to IAP (c-IAP-1, c-IAP-2 and XIAP) expression (step
7a), MDA-MB-468 cell anti-apoptosis/survival and che-
moresistance. In direct contrast, treatment of MDA-MB-
468 cells with an anti-miR-21 inhibitor reduces Bcl2
upregulation (step 6b). Subsequently, these changes result
in the inhibition of IAP (c-IAP-1, c-IAP-2 and XIAP) ex-
pression (step 7b), stimulation of apoptosis and enhance-
ment of chemosensitivity in MDA-MB-468 cells. Taken
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Figure 6 A proposed model for HA/CD44-mediated JNK/c-Jun signaling in the regulation of miRNA-21 production, oncogenesis and
chemoresistence in MDA-MB-468 cells. We propose that HA-CD44 binding (step 1) promotes JNK and c-Jun (also serine phosphorylated
JNK/c-Jun) (step 2). Subsequently, c-Jun (also p-c-Jun) translocates from the cytosol to the nucleus and interacts with an upstream/enhancer
region (containing AP1 binding sites) of the miR-21 promoter (step 3), resulting in miR-21 gene expression (step 4) and mature miR-21 production
(step 5). The resultant miR-21 then functions to upregulate the survival protein, Bcl2 (step 6a) and promotes MDA-MB-468 cell activation leading
to IAP (c-IAP-1, c-IAP-2 and XIAP) expression (step 7a), MDA-MB-468 cell anti-apoptosis/survival and chemoresistance. In direct contrast, treatment
of MDA-MB-468 cells with an anti-miR-21 inhibitor reduces Bcl2 upregulation (step 6b). Subsequently, these changes result in the inhibition of IAP
(c-IAP-1, c-IAP-2 and XIAP) expression (step 7b), stimulation of apoptosis and enhancement of chemosensitivity in MDA-MB-468 cells. Taken
together, these findings suggest that targeting HA/CD44-mediated JNK/c-Jun signaling pathways and miR-21 function may provide a new drug
target to sensitize tumor cell apoptosis/death and overcome chemotherapy resistance in MDA-MB-468 breast tumor cells.
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miR-21 function may provide new drug targets to sensitize
tumor cell apoptosis/death and overcome chemotherapy
resistance in MDA-MB-468 breast tumor cells.
Materials and methods
Cell culture
The cell line, MDA-MB-468 cells from ATCC, was iso-
lated in 1977 by R. Cailleau, et al., from a pleural effusion
of a 51-year-old Black female patient with metastatic
adenocarcinoma of the breast. This cell line was cultured
in ATCC-formulated Leibovitz’s L-15 Medium, Catalog
No. 30-2008, with 10% fetal bovine serum.
Antibodies and reagents
Monoclonal rat anti-CD44 antibody (Clone: 020; Isotype:
IgG2b; obtained from CMB-TECH Inc., San Francisco,
CA, USA) recognizes a determinant of the HA-bindingregion common to CD44 and its principal variant iso-
forms. This rat anti-CD44 was routinely used for HA-
related blocking experiments. Immunoreagents such as
rabbit anti-C-JUN antibody, mouse anti-Bcl-2 antibody
and goat anti-actin antibody were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Mouse
anti-c-IAP-1 antibody, mouse anti-c-IAP-2 and mouse
anti-XIAP antibody were from BD (Franklin Lakes, NJ,
USA). Rabbit anti-phospho-c-Jun [pS63] antibody, rabbit
anti-c-Jun antibody, rabbit anti-JNK[pS63] antibody and
rabbit anti-JNK antibody were from Cell Signaling
Technology (Beverly, MA, USA). JNK Inhibitor I,
420116 was purchased from EMD Millipore (Billerica,
MA, USA). Doxorubicin hydrochloride was from Sigma
Chemicals (St. Louis, MO). Healon HA polymers
(~500,000-dalton polymers), purchased from Pharmacia
& Upjohn Co. (Kalamazoo, MI), were prepared as de-
scribed previously [29,31,38].
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MDA-MB-468 cells were transfected with anti-miR-21
inhibitor (Ambion, catalog number, 17000) (30 nmol/l)
and its corresponding miRNA negative control (Ambion,
catalog number, 17010) (30 nmol/l) using Lipofectamine
2000 reagent (Invitrogen) for 24 hours. Cells were then
treated with HA or no HA in various experiments as de-
scribed below.Immunoblotting techniques
The NP-40 solubilized cell lysate materials from MDA-
MB-468 cells [untreated or pretreated with anti-CD44
antibody or JNK Inhibitor I, 420116 (20 μM) or vehicle
control] plus 50 μg/ml HA (or no HA) for various time in-
tervals (e.g. 0, 5min, 15min or 60min or 24 h) at 37°C] were
immunoblotted with rabbit anti-c-Jun antibody (2 μg/ml)
or rabbit anti-phospho-c-Jun [pS63] antibody (2 μg/ml) or
rabbit anti-c-JNK[pS183] antibody (2 μg/ml), respectively.
In some cases, cell lysate of MDA-MB-468 cells (trans-
fected with c-Jun siRNA or siRNA with scrambled se-
quences; or anti-miR-21 inhibitor or miRNA-negative
control; or without any treatment) followed by HA
(50 μg/ml) addition (or no HA or anti-CD44 antibody
pretreatment plus HA) at 37°C were also immunoblotted
using various immuno-reagents (e.g., mouse anti-Bcl-2
(2 μg/ml) or mouse anti-c-IAP-1 or mouse anti-c-IAP-2
antibody and anti-XIAP (2 μg/ml) or goat anti-actin
(2 μg/ml) (as a loading control), respectively.Chromatin immunoprecipitation assay
To examine whether c-Jun or phospho-c-Jun directly in-
teracts with the upstream promoter/enhancer region
(containing AP-1 binding site) of miR-21, chromatin im-
munoprecipitation (ChIP) assays was performed in
MDA-MB-468 cells [pretreated with anti-CD44 antibody
or JNK Inhibitor I, 420116 (20 μM)/vehicle control or
transfected with c-Jun siRNA or siRNA with scrambled
sequences] treated with HA (50 μg/ml) or without HA
using a kit (EZ ChIP) from Millipore Corp according to
the manufacturer’s instructions. Crosslinked chromatin
lysates were sonicated and diluted with ChIP sonication
buffer plus protease inhibitors, divided and incubated
with normal rabbit IgG or rabbit anti-c-Jun antibody or
rabbit phospho-c-Jun[pS63] antibody at 4°C overnight,
then precipitated with protein G agarose. Crosslinking
was reversed by overnight at 65°C incubation; DNA frag-
ments were then extracted with PCR purification kit, an-
alyzed by PCR and quantitated by PCR using primer
pairs specific for the miR-21 upstream promoter/enhan-
cer region containing the c-Jun binding sites: forward
primer: 5′-TGGATAAGGATGACGCACAG-3′ and re-
verse primer: 5′-TGGTTTGAACCAATTAATAAGGAAA-
3′ on an agarose gel as described previously [25,29,38,60].RNase protection assay analysis of mature miRNAs
Expression of miRNAs was qualitatively analyzed by
RNase protection assay. For RNase protection assay,
enriched small RNA isolated from MDA-MB-468 cells
[transfected with scrambled sequence siRNA with (or
without) anti-CD44 antibody or JNK Inhibitor I, 420116
(20 μM)/vehicle control or transfected with c-Jun siRNA
or siRNA or anti-miR-21 inhibitor or miRNA-negative
control in the presence or absence of HA for various
time intervals (e.g., 0, 5min, 10min, 15min, 30min or 2 h)
at 37°C] was enriched and purified using the mirVana
miRNA Isolation kit (Ambion). RNA concentrations
were verified by measuring absorbance (A260) on the
NanoDrop Spectrophotometer ND-1000 (NanoDrop).
The mirVana miRNA probe construction kit (Ambion)
was used to synthesize the 32P-labeled miR-21 antisense
probe and miR-191 probe loading control as described
previously [25,29,38].
Immunofluorescence staining
MDA-MB-468 cells (untreated or pretreated with anti-
CD44 antibody) were incubated with HA (50 μg/ml) at
37°C for 30 minutes or with no HA. These cells were
then fixed with 2% paraformaldehyde. Subsequently,
these cells were rendered permeable by ethanol treat-
ment followed by incubating with Texas Red-conjugated
anti-phospho-c-Jun[pS63] antibody or fluorescein (FITC)-
conjugated anti-c-Jun antibody followed by DAPI staining
(a marker for nucleus). These fluorescence-labeled sam-
ples were then examined with a confocal laser scanning
microscope.
Tumor cell growth and apoptosis assays
MDA-MB-468 cells were either untreated or pretreated
with anti-CD44 antibody or treated with JNK inhibitor,
420116 (20 μM) or transfected with c-Jun siRNA or siRNA
with scrambled sequences or anti-miR-21 or miRNA-
negative control] in the presence or absence of 50 μg/ml
HA, as above. These cells were then plated in 96-well
culture plates in 0.2 ml of Dulbecco’s modified Eagle’s
medium/F12 medium supplement (GIBCO, Grand Island,
NY) containing no serum for 24 h at 37°C in 5% CO2/95%
air. These cells (5 × 103 cells/well) were then incubated
with various concentrations of Doxorubicin (4 × 10−9 M-
1.75 × 10−5 M) with no HA or with HA (50 μg/ml). After
24h incubation at 37°C, MTT-based growth assays were
analyzed as described previously [25,30]. The percentage
of absorbance relative to untreated controls (i.e., cells
treated with neither HA nor chemotherapeutic drugs) was
plotted as a linear function of drug concentration. The
50% inhibitory concentration (IC50) was identified as a
concentration of drug required to achieve a 50% growth
inhibition relative to untreated controls. For apoptosis
assay, FITC-conjugated Annexin V (for measuring
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http://www.molecular-cancer.com/content/13/1/52apoptotic cells) using Apoptosis Detection Kit (Calbiochem,
San Diego, CA) was used according to the manufacturer’s
protocol.
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